Keryx Biopharmaceuticals, Inc. (KERX) Releases Quarterly Earnings Results, Misses Estimates By $0.60 EPS
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.60, MarketWatch Earnings reports. The company had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.51 million. Keryx Biopharmaceuticals had a negative return on equity of 1,122.28% and a negative net margin of 387.12%. The firm’s quarterly revenue was up 62.4% on a year-over-year basis. During the same quarter last year, the company posted ($0.42) earnings per share.
Keryx Biopharmaceuticals (KERX) traded down 4.98% during mid-day trading on Thursday, reaching $7.06. The company had a trading volume of 3,085,685 shares. Keryx Biopharmaceuticals has a 12-month low of $4.03 and a 12-month high of $8.38. The firm’s market capitalization is $765.77 million. The firm has a 50-day moving average price of $7.10 and a 200 day moving average price of $6.09.
Several brokerages have recently issued reports on KERX. Maxim Group reiterated a “buy” rating and set a $7.00 price target on shares of Keryx Biopharmaceuticals in a report on Monday, May 1st. BidaskClub downgraded shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Zacks Investment Research downgraded shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, July 17th. ValuEngine downgraded shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. Finally, Cowen and Company reiterated a “market perform” rating on shares of Keryx Biopharmaceuticals in a report on Tuesday. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $8.11.
ILLEGAL ACTIVITY NOTICE: “Keryx Biopharmaceuticals, Inc. (KERX) Releases Quarterly Earnings Results, Misses Estimates By $0.60 EPS” was reported by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/07/27/keryx-biopharmaceuticals-inc-kerx-releases-quarterly-earnings-results-misses-estimates-by-0-60-eps.html.
A number of hedge funds have recently bought and sold shares of KERX. OZ Management LP acquired a new stake in Keryx Biopharmaceuticals during the first quarter valued at $109,000. Usca Ria LLC acquired a new stake in Keryx Biopharmaceuticals during the first quarter valued at $128,000. Jane Street Group LLC acquired a new stake in Keryx Biopharmaceuticals during the first quarter valued at $141,000. Legal & General Group Plc increased its stake in Keryx Biopharmaceuticals by 1.2% in the first quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 300 shares in the last quarter. Finally, Lincoln Capital Corp increased its stake in Keryx Biopharmaceuticals by 13.1% in the first quarter. Lincoln Capital Corp now owns 30,300 shares of the biopharmaceutical company’s stock valued at $187,000 after buying an additional 3,500 shares in the last quarter. 62.26% of the stock is owned by institutional investors and hedge funds.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.